Cibus (NASDAQ:CBUS) Receives Buy Rating from HC Wainwright

Cibus (NASDAQ:CBUS)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a report released on Friday,Benzinga reports. They currently have a $25.00 target price on the stock. HC Wainwright also issued estimates for Cibus’ Q1 2025 earnings at ($0.66) EPS, Q2 2025 earnings at ($0.67) EPS, Q3 2025 earnings at ($0.69) EPS, Q4 2025 earnings at ($0.70) EPS and FY2029 earnings at $1.36 EPS.

Separately, Canaccord Genuity Group decreased their price target on shares of Cibus from $20.00 to $18.00 and set a “buy” rating for the company in a report on Wednesday, January 22nd.

Cibus Stock Performance

NASDAQ CBUS opened at $2.05 on Friday. Cibus has a one year low of $1.80 and a one year high of $23.18. The company has a 50-day simple moving average of $2.33 and a 200-day simple moving average of $3.33. The firm has a market capitalization of $54.23 million, a PE ratio of -0.09 and a beta of 2.04.

Cibus (NASDAQ:CBUS) last posted its quarterly earnings results on Thursday, March 20th. The company reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.68) by ($0.19). Cibus had a negative net margin of 10,724.78% and a negative return on equity of 28.17%. The business had revenue of $1.21 million during the quarter, compared to analyst estimates of $1.13 million. Equities analysts forecast that Cibus will post -2.96 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. HighTower Advisors LLC boosted its stake in Cibus by 20.6% during the 3rd quarter. HighTower Advisors LLC now owns 16,125 shares of the company’s stock valued at $52,000 after purchasing an additional 2,750 shares during the period. Charles Schwab Investment Management Inc. boosted its stake in Cibus by 14.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 49,285 shares of the company’s stock valued at $161,000 after purchasing an additional 6,276 shares during the period. Barclays PLC boosted its stake in Cibus by 35.1% during the 4th quarter. Barclays PLC now owns 27,375 shares of the company’s stock valued at $76,000 after purchasing an additional 7,106 shares during the period. Northern Trust Corp lifted its stake in shares of Cibus by 9.2% in the 4th quarter. Northern Trust Corp now owns 152,122 shares of the company’s stock worth $423,000 after acquiring an additional 12,832 shares during the period. Finally, IFP Advisors Inc bought a new position in shares of Cibus in the fourth quarter valued at approximately $36,000. 33.81% of the stock is owned by institutional investors and hedge funds.

About Cibus

Cibus, Inc, a agricultural biotechnology company, develops and licenses plant traits to seed companies for royalties. The company primarily focus on trait productivity in two areas, including productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients that enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases.